Adjuvant therapy is chosen according to clinical characteristics (lymph node status, tumor size, and tumor grade), patient physiologic status and age, and IHC status in three tumor receptors: estrogen receptor (ER), progesterone receptor, and HER2. This evidence concerns the gene ERBB2 and neoplasm.